Intravenous drug delivery in neonates: lessons learnt

2014 ◽  
Vol 99 (6) ◽  
pp. 590-594 ◽  
Author(s):  
C. M. T. Sherwin ◽  
N. J. Medlicott ◽  
D. M. Reith ◽  
R. S. Broadbent
Keyword(s):  
Drug Delivery ◽  
Intravenous Drug ◽  
Lessons Learnt

scholarly journals Overcoming physiological barriers by nanoparticles for intravenous drug delivery to the lymph nodes

2021 ◽  
pp. 153537022110107
Author(s):  
Noah Trac ◽  
Eun Ji Chung
Keyword(s):  
Drug Delivery ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Cancer Metastasis ◽  
Subcutaneous Administration ◽  
Mononuclear Phagocyte ◽  
Intravenous Drug ◽  
Rapid Clearance ◽  
Nanoparticle Design ◽  
Lymph Node Targeting

The lymph nodes are major sites of cancer metastasis and immune activity, and thus represent important clinical targets. Although not as well-studied compared to subcutaneous administration, intravenous drug delivery is advantageous for lymph node delivery as it is commonly practiced in the clinic and has the potential to deliver therapeutics systemically to all lymph nodes. However, rapid clearance by the mononuclear phagocyte system, tight junctions of the blood vascular endothelium, and the collagenous matrix of the interstitium can limit the efficiency of lymph node drug delivery, which has prompted research into the design of nanoparticle-based drug delivery systems. In this mini review, we describe the physiological and biological barriers to lymph node targeting, how they inform nanoparticle design, and discuss the future outlook of lymph node targeting.

Intravenous Drug Delivery

2021 ◽  
pp. 1-9
Author(s):  
Sebastian Scioli Montoto ◽  
Maria Esperanza Ruiz
Keyword(s):  
Drug Delivery ◽  
Intravenous Drug

Second Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems—2008

2009 ◽  
Vol 66 (2) ◽  
pp. 185-192 ◽  
Author(s):  
Michael D. Sanborn ◽  
Mary L. Moody ◽  
Kathleen A. Harder ◽  
Ginette A. Pepper ◽  
Matthew Scanlon ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Intravenous Drug ◽  
Consensus Development ◽  
Consensus Development Conference

Influence of specific gravity on intravenous drug delivery

1981 ◽  
Vol 99 (4) ◽  
pp. 658-661 ◽  
Author(s):  
Percy Rajchgot ◽  
Ingeborg C. Radde ◽  
Stuart M. MacLeod
Keyword(s):  
Drug Delivery ◽  
Specific Gravity ◽  
Intravenous Drug

Third Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems—2018

2019 ◽  
Vol 77 (3) ◽  
pp. 215-220
Author(s):  
Michael Gabay ◽  
John B Hertig ◽  
Dan Degnan ◽  
Maureen Burger ◽  
Angela Yaniv ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Expert Panel ◽  
Healthcare Providers ◽  
Delivery Systems ◽  
Consensus Conference ◽  
Intravenous Drug ◽  
Drug Shortages ◽  
The Third ◽  
The Impact

Abstract Purpose The Third Consensus Conference on the Safety of Intravenous Drug Delivery Systems was convened to evaluate the benefits and risks of available systems and assess ongoing threats to the safety of intravenous drug delivery. Summary The Third Consensus Conference on the Safety of Intravenous Drug Delivery Systems convened in Chicago, Illinois in November 2018. An expert panel of healthcare providers with experience in medication quality and safety, pharmacy and nursing operations, information technology, and/or sterile compounding led the conference. An experienced audience of approximately 30 healthcare leaders provided feedback to the panel via preconference survey and during the conference. Additionally, expert speakers presented on a range of issues, including the effects of drug shortages, the impact of standards and guidelines, and patient and administrator perspectives on the importance of intravenous drug delivery safety. Conclusion At the end of the conference, the expert panel concluded that manufacturer ready-to-use products remain the safest intravenous drug delivery system due to their many benefits and low overall risk profile. The panel identified various ongoing threats to the safety of intravenous drug delivery, with major concerns including the impact of drug shortages and lack of intravenous product standardization. Finally, the panel agreed upon a series of statements designed to advance the safety of intravenous drug delivery in healthcare institutions.

scholarly journals The Safety of Intravenous Drug Delivery Systems: Update on Current Issues Since the 2009 Consensus Development Conference

2018 ◽  
Vol 53 (6) ◽  
pp. 408-414 ◽  
Author(s):  
Ryan Rodriguez
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Point Of Care ◽  
Regulatory Compliance ◽  
Medication Administration ◽  
Delivery Systems ◽  
Intravenous Drug ◽  
Consensus Development ◽  
The Third ◽  
Consensus Development Conference

This review was prepared in advance of the Third Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems that was held at the W Hotel in Chicago, Illinois, from November 1 through 3, 2018. The purpose of this conference was to evaluate the safety of intravenous (IV) infusion systems used for medication administration. The expert panel of pharmacists, physicians, and nurses updated the findings of the Second Consensus Development Conference in 2009 that reviewed 5 IV drug delivery systems (manufacturer ready to use, outsourced ready to use, point-of-care activated, pharmacy compounded, and nonpharmacy compounded at point of care) with regard to applicability, ease of use, regulatory compliance, cost, safety, and implementation. The Third Consensus Development Conference expanded on previous findings by reviewing proceedings related to new standards, legislation, technologies, and shortage-related challenges related to IV medication administration that have been published since 2009. Invited faculty and audience members participated in revising a preliminary report summarizing these changes during the meeting.

Sign in / Sign up

Export Citation Format

Share Document